Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > TIME TO ROLL

<< Previous

Bullboard Posts

Next >>

Post by angeloeton Apr 14, 2022 9:53am

181 Views

Post# 34603429

TIME TO ROLL

With Echelon finally out of the way, looks like we're about to fly. Time to ride this. 1.2 billion in revenue alone from ACP, and that doesn't even include the Shapiro deal, 430 million patients at 20,000$s per treatment, even if they have just a 10% share of that market -43bil$s in revenue-. We're about to make paper son, loooooool !!

<< Previous

Bullboard Posts

Next >>

Critical raw materials pioneer drives Europe’s clean energy transition